Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures
- 1 September 1994
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 48 (6) , 1145-1154
- https://doi.org/10.1016/0006-2952(94)90151-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemiaBlood, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter platesBritish Journal of Cancer, 1992
- A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 daysAnti-Cancer Drugs, 1992
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- DNA TOPOISOMERASESAnnual Review of Biochemistry, 1985
- Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic familyNucleic Acids Research, 1985
- The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphomaCell, 1983